Autopsy report · NCT00816686

A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer

“Trial was terminated due to the need to re-formulate the study drug.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months after it had already started.
• Ran for about 1 year 6 months before it stopped.
• 7 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Astellas Pharma Inc

Sponsor type

Industry

Conditions

Carcinoma, Renal Cell; Kidney Neoplasms; Kidney Diseases

Interventions

AGS-16M18

Participants

7

Sites

2

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.